The driving risk associated with sleep apnoea is one of the most practically significant findings in the field, because unlike most of the other consequences described in this series, it has immediate third-party implications. A person with untreated severe OSA sitting behind the wheel of a car is not only putting themselves at risk. They are putting other road users at risk through a level of cognitive impairment equivalent to being over the legal drink-drive limit.
I am aware that this section may cause some anxiety for people who have been recently diagnosed or who are reading this having recognised themselves in the description of OSA. The intention is not to alarm but to inform clearly, because the data on treatment are equally important: CPAP that is used consistently reduces accident risk to background levels. The impairment is reversible. What is not reversible is the consequences of a collision that happens while it remains untreated.
The Road Traffic Accident Risk
A meta-analysis of 49 studies covering more than 4.2 million people found that OSA patients have an odds ratio of 2.36 for involvement in a road traffic accident. An odds ratio of 2.36 means people with OSA are 2.36 times as likely to be involved in a crash compared with drivers without OSA. To put that in more intuitive terms: for every 100 crashes involving drivers without OSA over a given period of equivalent driving exposure, you would expect approximately 236 crashes involving drivers with untreated OSA. That is not a marginal elevation. It is roughly the crash risk associated with a blood alcohol level of 0.05 to 0.08 per cent — in the range of the UK drink-drive limit.
This risk elevation is dose-dependent: drivers with more severe OSA, and specifically those with more severe daytime sleepiness (as measured by the Epworth Sleepiness Scale), have progressively higher accident risk than those with mild symptoms. The dose-response pattern is consistent with a genuine causal relationship rather than a coincidental one.
Drivers with untreated severe OSA face more than double the crash risk of drivers without the condition — roughly equivalent to driving near the legal blood alcohol limit. CPAP that is consistently used returns accident risk to background levels.
Why OSA Impairs Driving: The Mechanism
The common assumption is that sleep apnoea increases crash risk primarily because drivers fall asleep at the wheel. Falling asleep at the wheel does happen, and it is dramatically more common in OSA patients than in the general population. But it is not the primary mechanism. Most crashes associated with OSA occur because of impaired sustained attention, slowed reaction time, and impaired hazard detection — consequences of the chronic sleep fragmentation and hypoxia that affect cognitive performance even in drivers who feel alert and do not believe they are at risk of falling asleep.
This is important because it means that OSA patients cannot reliably self-assess their own driving fitness. The impairment in vigilance and reaction time that characterises moderate-to-severe OSA occurs in the same cognitive domains that govern self-awareness of impairment. A driver with severe OSA may genuinely believe they are safe to drive — and be wrong — in the same way that a significantly intoxicated person may genuinely believe they are not affected by alcohol.
The specific cognitive impairments most relevant to driving are well characterised. Sustained attention impairment in OSA (discussed in detail on the cognitive impairment page) means that a driver may be fully alert at the start of a journey and increasingly impaired over time, failing progressively to detect hazards, monitor peripheral events, and maintain lane position. Reaction time slows. Emergency braking distance increases. Higher-order driving tasks — merging at motorway junctions, complex junctions, reading evolving traffic patterns — require cognitive resources that are systematically reduced by chronic sleep fragmentation.
The Legal Position in the UK
UK DVLA guidance is clear and has practical legal consequences. Group 1 licence holders (private car drivers) who have been diagnosed with OSA causing excessive daytime sleepiness must stop driving and notify the DVLA. The licence can be returned after treatment is established and excessive sleepiness has resolved, subject to satisfactory medical evidence. Group 2 licence holders (lorry, bus, and coach drivers) face stricter requirements: moderate-to-severe OSA must be treated and compliance with CPAP confirmed before driving can continue.
EU Directive 2014/85/EU — which established the European framework for OSA and driving — requires that commercial vehicle drivers with untreated moderate-to-severe OSA must not drive commercial vehicles. This directive applies to driving licences issued across EU member states and has influenced clinical practice guidelines across Europe, including the UK. Commercial drivers in the haulage and passenger transport industries are subject to regular fitness assessments, and OSA is specifically mentioned as a condition requiring active management.
The practical implication for patients who drive professionally is that a diagnosis of OSA is not itself the end of their career, provided treatment is established and adhered to. But failing to disclose or address the diagnosis while continuing to drive creates both legal liability and a genuinely elevated crash risk that is not a theoretical concern.
Workplace Accidents
The elevated injury risk from OSA is not limited to the road. A meta-analysis found that OSA patients have odds ratio of 2.18 for workplace accidents compared with those without OSA — meaning they are 2.18 times as likely to be involved in a workplace injury. The mechanism is the same as for driving: impaired sustained attention, slowed reaction time, and reduced capacity to detect and respond to hazards. In workplaces where safety depends on alertness — construction, manufacturing, engineering, healthcare, logistics — this elevated risk is practically important.
Some industries already require fitness-for-work assessments that include screening for excessive daytime sleepiness. The evidence supports expanding this practice to include systematic OSA screening in safety-critical roles, and occupational health teams increasingly recognise OSA as a modifiable safety hazard in the workplace.
What Treatment Does to Accident Risk
The treatment data are encouraging and clinically important. CPAP therapy, in patients who use it consistently — generally defined as more than four hours per night — reduces driving accident risk to a level essentially equivalent to that of drivers without OSA. A meta-analysis of studies examining accident rates before and after CPAP initiation found that crash rates in treated patients were reduced to within the range of the general driving population.
The mechanism is direct: CPAP restores normal sleep architecture, eliminates the overnight hypoxia and fragmentation responsible for daytime cognitive impairment, and substantially improves sustained attention, reaction time, and psychomotor vigilance — the specific cognitive functions most relevant to safe driving. In trials measuring driving simulator performance, CPAP-treated patients show significant improvements in lane deviation, reaction time, and hazard detection compared with untreated controls.
For professional drivers, the evidence is sufficient to support reinstatement of driving privileges after a period of consistent CPAP use and demonstrated improvement in sleepiness scores. The clinical evidence required varies by licence group and jurisdiction, but the principle is consistent: effective treatment restores fitness to drive.
References
[1] Luzzi V et al. Correlations of obstructive sleep apnea syndrome and daytime sleepiness with the risk of car accidents. Journal of Clinical Medicine. 2022. 49 studies, 4.2 million participants; pooled OR 2.36 for road traffic accidents in OSA patients; dose-response with Epworth Sleepiness Scale score.
[2] Garbarino S et al. Obstructive sleep apnea and workplace accidents: a systematic review and meta-analysis. Journal of Clinical Medicine. 2020. Meta-analysis; OR 2.18 for workplace accidents in OSA patients; dose-dependent with sleepiness severity.
[3] George CF. Reduction in motor vehicle collisions following treatment of sleep apnoea with nasal CPAP. Thorax. 2001. Prospective Canadian cohort; crash rate reduced by approximately 70% in patients with good CPAP adherence versus pre-treatment period.
[4] Burks SV et al. Nonadherence with employer-mandated sleep apnea treatment and increased risk of serious truck crashes. Sleep. 2016. Large trucking industry cohort; non-adherent OSA drivers had crash rate 5-fold higher than drivers without OSA; adherent CPAP drivers had crash rate equivalent to non-OSA drivers.
[5] European Commission. Commission Directive 2014/85/EU amending Directive 2006/126/EC on driving licences. Official Journal of the European Union. 2014. EU directive establishing framework for OSA screening, diagnosis, and treatment requirements for Group 1 and Group 2 licence holders across member states.
[6] DVLA. Assessing fitness to drive — a guide for medical professionals. Driver and Vehicle Licensing Agency. Updated 2023. UK guidance: Group 1 — must notify DVLA, stop driving if excessive daytime sleepiness present; Group 2 — must demonstrate effective treatment and compliance before returning to driving.
[7] Pizza F et al. Driving simulator performance in patients with obstructive sleep apnea before and after CPAP treatment. Sleep Medicine. 2022. Systematic review; CPAP treatment significantly improved lane deviation, reaction time, and hazard detection in driving simulator studies.
Contact Professor Vik Veer
If you would like to discuss a sleep assessment or arrange a consultation, please use the details below.
Private secretary: 0207 458 4584